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Abstract: Metal complexes of heterocyclic sulfonamides possessing carbonic anhydrase (CA) inhibitory
properties were recently shown to be useful as intraocular pressure (IOP) lowering agents in experimental
animals, and might be developed as a novel class of antiglaucoma drugs. Here we report the synthesis of a
heterocyclic sulfonamide CA inhibitor and of the metal complexes containing main group metal ions, such as
Be(II), Mg(II), AI(III), Zn(II), Cd(II) and Hg(II) and the new sulfonamide as well as 5-amino-l,3,4-
thiadiazole-2-sulfonamide as ligands. The new complexes were characterized by standard physico-chemical
procedures, and assayed as inhibitors of three CA isozymes, CA I, II and IV. Some of them (but not the
parent sulfonamides) strongly lowered IOP in rabbits when administered as a 2% solution into the eye.
Introduction
Sulfonamides possessing carbonic anhydrase (CA, EC 4.2.1.1) inhibitory properties [2] such as
acetazolamide 1, methazolamide 2, ethoxzolamide 3 and dichlorophenamide 4 have been used for more than
40 years as pressure lowering systemic drugs in the treatment of open-angle glaucoma [3,4]. Their effect is
due to inhibition of at least two CA isozymes present within cilliary processes of the eye, ie, CA II and CA
IV, which is followed by lowered bicarbonate formation and reduction of aqueous humor secretion [5-7].
Their main drawback is constituted by side effects such as fatigue, augmented diuresis, or paresthesias, due
to CA inhibition in other tissues/organs than the target one, ie, the eye [8].
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The above-mentioned side effects are absent in the case in which the inhibitor has topical activity,
and is applied directly into the eye. This route has been demonstrated only in 1983 by Maren’s group [9] and
was followed by the development of the first clinical agent of this type, dorzolamide 5 [10,11 ]. Dorzolamide
(Trusopt) has been introduced in clinical use in 1995 in USA and Europe and it constituted the beginning of
a radically new treatment of glaucoma, devoid of the severe side effects observed with the systemic
inhibitors [4-6]. The success of topical antiglaucoma CA inhibitors fostered much research in the synthesis
and clinical evaluation of other types of such compounds [12-15].
307Vol. 4, No. 6, 1997 Metal Complexes ofHeterocyclic Sulfonamides:
A New Class ofAntiglaucoma Agents
On the other hand, metal complexes of heterocyclic sulfonamides of type 1-5 have been recently
prepared by two groups 16-20], and it was proved that they possess much stronger CA inhibitory properties
than the sulfonamides from which they were prepared 18-22]. Although the mechanism ofCA inhibition of
the metal complexes is presently unknown, it was hypothesized that their increased inhibitory power might
be due to two processes, occurring separately or in concert, ie, (i) dissociation of the complex inhibitor in
sulfonamide anions and metal ions (in diluted solution), which in turn both interact thereafter with the
enzyme, at different binding sites, and (ii) direct interaction of the undissociated complex with the enzyme,
and more specifically with the hydrophilic patch at the entrance of CA II active site [23], this being the
isozyme most susceptible to inhibition with this class of compounds [2,22]. Whether initially the first
mechanism of action mentioned above was favored by us [22], recent evidences suggested that the
undissociated complex might be the inhibitory species, at least for some isozymes [24]. Since metal
complexes are much more inhibitory than the parent sulfonamide from which they were prepared, it appeared
of interest to test whether this property might be useful for their use in lowering IOP in experimental animals
and whence as a possible glaucoma therapy. Recently we proved [25, 26] that some metal complexes of
heterocyclic sulfonamides (which themselves do not possess IOP lowering properties) act as very powerful
such agents when administered as diluted solutions directly into the eye of experimental animals, and would
thus offer the possibility of developing such totally novel drugs.
Here we report the synthesis of a heterocyclic sulfonamide possessing strong CA inhibitory
properties, ie, 5-(chloroacetamido)-l,3,4-thiadiazole-2-sulfonamide, and of the metal complexes of this
sulfonamide and of 5-amino-1,3,4-thiadiazole-2-sulfonamide, containing some main group metal ions. The
new compounds have been characterized by standard physico-chemical procedures, and were assayed as
inhibitors of three CA isozymes, hCA I, hCA II and bCA IV (h human; b bovine; these are the isozymes
considered to play a critical role in aqueous humour secretion within the eye of higher vertebrates [2-5]).
Materials and Methods
Melting points were recorded with a heating plate microscope and are not corrected. IR spectra were
recorded in KBr pellets with a Carl Zeiss IR-80 instrument. 1H-NMR spectra were recorded in DMSO-d6 as
solvent, with a Bruker CPX200 instrument. Chemical shifts are reported as values, relative to Me4Si as
internal standard. Conductimetric measurements were done at room temperature (1 mM concentration of
complex) in DMSO solution with a Fisher conductimeter. Elemental analyses were done by combustion for
C, H, N with an automated Carlo Erba analyzer, and gravimetrically for the metal ions, and were 0.4% of the
theoretical values. Thermogravimetric measurements were done in air, at a heating rate of 10C/min., with a
Perkin Elmer 3600 thermobalance.
Sulfonamides used as standards in the enzymatic assay (except for 5), acetazolamide, pyridine, and
chloroacetyl chloride used for the preparation of compound 7, solvents as well as inorganic reagents were
from Sigma, Merck and Carlo Erba. 5-Amino-l,3,4-thiadiazole-2-sulfonamide 6 was prepared from
acetazolamide by literature procedures [27], by desacetylation with concentrated hydrochloric acid, followed
by neutralization with sodium bicarbonate of the corresponding hydrochloride (Scheme 1). Dorzolamide
hydrochloride 5 was from Merck, Sharp and Dohme or was prepared as described by Ponticello et al 10,11 ].
Human CA and CA II cDNAs were expressed in Escherichia coli strain BL21 (DE3) from the
plasmids pACA/hCA I and pACAdaCA II described by Forsman et al. [28] (the two plasmids were a gift
from Prof. Sven Lindskog, Umea University, Sweden). Cell growth conditions were those described by
Lindskog’s group [29], and enzymes were purified by affinity chromatography according to the method of
Khalifah et al [30]. Enzyme concentrations were determined spectrophotometrically at 280 nm, utilizing a
molar absorptivity of 49 mM-l.cm-1 for hCA and 54 mM-l.cm-1 for hCA II, respectively, based on M
28.85 kDa for hCA I, and 29.3 kDa for hCA II, respectively [31,32]. bCA IV was isolated from bovine lung
microsomes as described by Maren et al, and its concentration has been determined by titration with
ethoxzolamide [33].
Synthesis of5-(chloroacetamido)- l, 3, 4-thiadiazole-2-sulfonamide 7
An amount of 1.80 g (10 mmol) of 5-amino-1,3,4-thiadiazole-2-sulfonamide 6 was suspended in 20 mL of
anhydrous acetonitrile and 0.9 mL (0.87g, 11 mmol) of pyridine added. The mixture was magnetically stirred
at 4 C for 10 minutes, then 10.5 mmol of monochloroacetyl chloride, dissolved in 3 mL acetonitrile, were
added dropwise for 5 min, and stirring was continued for other 2 hours at room temperature. After an
additional 30 min of refluxation, followed by cooling, the precipitated crystals were filtered and
recrystallized from ethanol. Yield of 62% white crystals, mp 246-248 o lit [34] mp IR (KBr), cm-l: 590,
610, 660, 790, 935, 1090, 1115, 1170, 1350, 1400, 1550, 1650, 1720, 2870, 3280 3370 (broad); UV
spectrum, ,max, nm (lg): 255 (3.50); 288 (4.37) H-NMR (DMSO-d6), i, ppm: 2.96 (s, 2H, CH2); 8.20 (s,
2H, SOzNH2); 12.22 (s, 1H, CONH). Analysis, found: C, 18.56; H, 1.88; N, 21.76; S, 24.62 %;
C4HsC1N403S2 requires" C, 18.72; H, 1.96; N, 21.83; S, 24.98 %.
Generalprocedurefor the preparation ofcompounds 8-20
An amount of 6 mmol of sodium salt of sulfonamides 6 or 7 was prepared by reacting the corresponding
sulfonamide with the required amount of an alcoholic 1N NaOH solution, in ethanol as solvent. To this
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solution was added the aqueous metal salt (Zn(II), Mg(II), AI(III), Cd(II) chlorides, and Be(II), Pb(II) and
Hg(II) nitrate) solution, working in molar ratios RSOzNH- Mn+ of 2:1 for the divalent cations and 3:1 for
the trivalent cation, respectively. The aqueous-alcoholic reaction mixture was heated on a steam bath for one
hour, adjusting the pH at 7 if necessary, and after being cooled at 0 C the precipitated complexes were
filtered and thoroughly washed with alcohol-water 1:1 (v/v) and air dried. Yields were in the range of 85-90
%. The obtained white powders of compounds 8-20 melted with decomposition at temperatures higher than
350 C, and were poorly soluble in water and alcohol, but had good solubilities in DMSO, DMF as well as
mixtures ofDMSO-water, DMF-water.
Pharmacology
Carbonic anhydrase inhibition
Initial rates of 4-nitrophenyl acetate hydrolysis catalysed by different CA isozymes were monitored
spectrophotometrically, at 400 rim, with a Cary 3 instrument interfaced with an IBM compatible PC [35].
Solutions of substrate were prepared in anhydrous acetonitrile; the substrate concentrations varied between
2.10-2 and 1.10-6 M, working at 25C. A molar absorption coefficient of 18,400 M-l.cm-1 was used for the
4-nitrophenolate formed by hydrolysis, in the conditions of the experiments (pH 7.40), as reported in the
literature [35]. Non-enzymatic hydrolysis rates were always subtracted from the observed rates. Duplicate
experiments were done for each inhibitor concentration, and the values reported throughout the paper are the
mean of such results. Stock solutions of inhibitor (1 mM) were prepared in distilled-deionized water with 10-
20% (v/v) DMSO (which is not inhibitory at these concentrations [2]) and dilutions up to 0.01 nM were done
thereafter with distilled-deionized water. Inhibitor and enzyme solutions were preincubated together for 10
min at room temperature prior to assay, in order to allow for the formation of the E-I complex. The inhibition
constant KI was determined as described by Pocket and Stone [35]. Enzyme concentrations were 3.3 nM for
hCA II, l0 nM for hCA and 34 nM for bCA IV (this isozyme has a decreased esterase activity [36] and
higher concentrations had to be used for the-measurements).
Measurement oftonometric lOP
Adult male New Zealand albino rabbits weighing 2-3 kg were used in the experiments (three animals were
used for each inhibitor studied). The experimental procedures conform to the Association for Research in
Vision and Ophthalmology Resolution on the use of animals. The rabbits were kept in individual cages with
food and water provided ad libitum. The animals were maintained on a 12 h: 12 h light/dark cycle in a
temperature controlled room, at 22-26 C. Solutions of inhibitors (2 %, by weight) were obtained in DMSO-
water (2:3, v/v) due to the low water solubility of some of these derivatives. Control experiments with
DMSO (at the same concentration as that used for obtaining the inhibitors solutions showed that it does not
possess IOP lowering or increasing effects.
IOP was measured using a Digilab 30R pneumatonometer (BioRad, Cambridge, MA, USA) as described by
Maren’s group [37-39]. The pressure readings were matched with two-point standard pressure measurements
at least twice each day using a Digilab Calibration verifier. All IOP measurements were done by the same
investigator with the same tonometer. One drop of 0.2 % oxybuprocaine hydrochloride (novesine, Sandoz)
diluted 1"1 with saline was instilled in each eye immediately before each set of pressure measurements. IOP
was measured three times at each time interval, and the means reported. IOP was measured first immediately
before drug administration, then at 30 min after the instillation of the pharmacological agent, and then each
30 minutes for a period of several hours. For all IOP experiments drug was administered to only one eye,
leaving the contralateral eye as an untreated control. The ocular hypotensive activity is expressed as the
average difference in IOP between the treated and control eye, in this way minimizing the diurnal, seasonal
and interindividual variations commonly observed in the rabbit [37-39]. All data are expressed as mean SE,
using a one-tailed test.
Results and Discussion
Reaction of 5-amino-l,3,4-thiadiazole-2-sulfonamide 6 [19b] with chloroacteyl chloride in the
presence of pyridine afforded 5-(chloroacetamido)-l,3,4-thiadiazole-2-sulfonamide 7, by the procedure
already reported by Young et al. [34] (Scheme 1).
The sulfonamide 7 has been characterized by elemental analysis and spectroscopic methods which
confirmed its structure (only its m.p. has been reported in ref. [34]). The sodium salt of sulfonamides 6 and 7,
obtained in situ from the corresponding sulfonamide and sodium hydroxide, were then used for the
preparation of coordination compounds, containing the following metal ions: Be(II), Mg(II), Al(III), Zn(II),
Cd(II) and Hg(II). Mention should be made that although 5-amino-l,3,4-thiadiazole-2-sulfonamide 6 is the
parent compound of important sulfonamide CA inhibitors, such as acetazolamide, benzolamide,
methazolamide, etc., its coordination chemistry has been scarcely investigated up to now [22, 40].
The new complexes prepared in this work are shown in Table I. Both compounds containing the
sulfonamide-deprotonated species of sulfonamide 7 (LH), as well as complexes in which the anion of 5-
amino-1,3,4-thiadiazole-2-sulfonamide (tda) act as ligands, have been prepared. In fact in another work [40]
it was documented that in some cases, sulfonamides derived from this ring system may undergo hydrolysis to
309Vol. 4, No. 6, 1997 Metal Complexes ofHeterocyclic Sulfonamides."
A New Class ofAntiglaucoma Agents
the moiety substituting the 5 position, with the formation of 5-amino-l,3,4-thiadiazole-2-sulfonamide 6,
which thereafter coordinates metal ions present in solution.
CIH N
Scheme 1
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Thus, the X-ray crystal structure of the complex [Zn(tda)2(NH3)].H20 prepared in this way has recently been
reported by this group [40]. On the other hand, when the ligand 7 has not been hydrolyzed (during the
preparation of the coordination compounds) in the presence of the metal ion to 5-amino-l,3,4-thiadiazole-2-
sulfonamide and chloroacetate, the metal complexes contining 6 as ligand have been prepared from the last
(pure) compound (as sodium salt) and the corresponding metal salt, by the general procedure described in the
Experimental part.
Table I: Prepared complexes 8-20, containing the conjugate bases of sulfonamides 6 and 7 as ligands and
their elemental analysis data. L stands for the sulfonamide deprotonated species of 7, whereas tda for the
sulfonamide deprotonated species of 5-amino-1,3,4-thiadiazole-2-sulfonamide 6.
No. Complex Yield Analysis (calculated/found)
(%) %Ma %Cb %Hb %Nb
8 [Be(tda)2] 78 2.4/2.5 13.0/13.1 1.6/1.3 30.4/30.2
9 [Mg(tda)2].3 H20 76 5.5/5.1 11.0/10.8 2.7/2.3 25.6/25.5
10 [Zn(tda)2] 83 15.4/15.0 11.3/11.4 1.4/1.1 26.4/26.4
11 [Cd(tda)2] 90 23.8/24.1 10.2/10.1 1.2/1.2 13.7/23.3
12 [Hg(tda)2] 95 35.8/35.7 8.5/8.1 1.0/1.2 20.0/19.8
13 [Pb(tda)z(OH2)2] 84 34.4/34.7 7.9/7.9 1.6/1.3 18.6/18.5
14 [Al(tda)3] 72 4.7/4.4 12.7/12.8 1.6/1.6 29.7/29.6
15 [BeL2] 75 1.7/1.6 18.4/18.1 1.5/1.5 21.5/21.3
16 [ALL3] 59 3.4/3.5 18.1/17.9 1.5/1.3 21.1/20.8
17 [ZnL2] 87 11.3/11.5 16.6/16.2 1.3/1.4 19.4/19.3
18 [CdL2] 88 18.0/18.1 15.3/14.9 1.2/1.1 17.9/17.8
19 [HgL2] 92 28.1/28.3 13.4/13.3 1.1/1.2 15.7/15.6
20 [PbLz(OH2)2] 95 27.4/27.2 12.7/12.5 1.0/1.0 14.8/14.6
aBy gravimetry; bBy combustion.
The new complexes have also been characterized by spectroscopic, conductimetric and
thermogravimetric measurements (Table II). By comparing the IR spectra of the complexes and the
corresponding ligands, the following observations should be made: (i) the shift of the two sulfonamido
vibrations (both the symmetric as well as the the assymetric one), towards lower wavenumbers in the spectra
of the complexes, as compared to the spectra of the corresponding ligand (Table II), as already documented
previously for similar complexes [13-22]. This is a direct indication that the deprotonated sulfonamido
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moieties of the ligands interacts with the metal ions in the newly prepared coordination compounds; (ii) the
amide vibrations (the most intense such bands at 1670-1680 cm-1) of ligand 7 appear unchanged in the IR
spectra of complexes 15-20 (data not shown), suggesting that these moieties do not participate in
coordination of the metal ions; (iii) the C-N stretching vibration in the spectra of the prepared complexes is
shifted with 5-20 cm-1 towards lower wavenumbers, as compared to the same vibration in the spectra of
sulfonamides 6 and 7, indicating that one of the endocyclic nitrogens of the thiadiazolic ring (presumably N-
3) acts as donor atom, as already documented by X-ray crystallographic and spectroscopic determinations on
complexes of other sulfonamides (such as 1-3) with divalent metal ions [13-22] (Table II); (iv) changes in the
region 3100-3160 cm-, as the bands present in the spectra of sulfonamides 6, 7 are present in the spectra of
complexes 8-20 too, but they are not well resolved, and have a smaller intensity. This is probably due to
deprotonation of the SO2NH2 moiety and participation in the binding of cations; (v) the amino vibrations
from 3320 cm- in the spectra of 6 appear unchanged in the spectra of its complexes 8-14 (data not s.hown).
In the 1H-NMR spectra of compound 6 and its metal complexes, the signal of the amino group has
been evidenced as a broad singlet centered at 4.54 ppm (Table II), which is not exchangeable by addition of
D20 into the NMR tube, in contrast to the sulfonamido NH2 protons (which readily exchange). This proves
that the 5-amino moiety is not involved in binding the metal ions, as already shown in the X-ray
crystallographic work of the complex [Zn(tda)z(NH3)].H20 previously reported [40]. For sulfonamide 7 the
CONH proton resonates as a singlet at 12.22 ppm. In complexes 15-20 only very minor shifts of this signal
were evidenced (Table II), proving basically that the CONH moiety does not interact with the metal ions in
these complexes.
Table II: Spectroscopic, thermogravimetric and conductimetric data for compounds 6-20.
Comp. IR Spectraa ,cm-1 1H-NMR Spectrab
v(SO2)S; v(SO2)as v(C=N) CONH, i (ppm)
TG analysisc
calc./found
Conductimetryd
AM (-1 x cm2x mol-)
6 1170; 1350 1610 A e 2
8 1150; 1300 1600 A e 7
9 1150; 1305 1600 A 12.3/12.1f 4
10 1145; 1300 1600 A e 5
11 1145; 1305 1600 A e 3
12 1140; 1300 1590 A e 2
13 1145; 1300 1605 A 5.9/5.7g 2
14 1150; 1300 1605 A e 6
7 1170; 1350 1610 12.22 (1H) e 3
15 1130; 1335 1605 12.19 (2H) e 4
16 1140; 1330 1610 12.18 (3H) e 2
17 1140; 1330 1610 12.20 (2H) e 9
18 1150; 1330 1605 12.18 (2H) e 3
19 1140; 1335 1600 12.19 (2H) e 2
20 1145; 1330 1600 12.21 (2H) 4.7/4.8g 8
a In KBr; bin DMSO-d6; A the signal of the 5-amino group of 6 (appearing in the ligand at 4.54 ppm as a
broad singlet) appears at the same chemical shift (4.50 4.55 ppm) in complexes 8-14; cWeight loss between
70-250 C; d mM solution, in DMF, at 25C; e No weight loss seen under 250 C; fCorresponding to three
lattice water molecules lost at 70-110C, and gCorresponding to two coordinated water molecules, lost at
160-180 C.
Thermogravimetric analysis showed the presence of uncoordinated water molecules in the molecule
of complex 9 (the three waters were lost in a single step, between 70-110 C) and of coordinated water in the
molecules of the lead(II) derivatives 13 and 20. All these compounds behaved as non-electrolytes in DMF as
solvent (Table II). Mention should be made that the Mg(II) complex of sulfonamide 7 could not be isolated.
Instead, only the correponding complex of 5-amino-l,3,4-thiadiazole has been obtained from reaction
mixtures containing magnesium salts and the sodium salt of 7, probably due to a metal ion assisted
hydrolysis of 7 to 6 and chloroacetate. Generally such hydrolytic processes involve highly acidic conditions
and prolonged heating of the 5-alkylamido-1,3,4-thiadiazole-2-sulfonamide derivatives [41 ], but they might
become milder by taking into account the putative catalytic effect ofMg2+ ions reported here.
The data shown above lead to the conclusion that ligand 7 shares a common coordination chemistry
with acetazolamide 1 with which it is structurally related, whereas 6 probably also behaves similarly to
acetazolamide in the sense that the 5-amino group seems not to be involved in coordinating metal ions, at
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least in the complexes reported by us here (and also in the compound characterized by X-ray crystallography
mentioned above [40]). Thus, in all complexes reported here these sulfonamides (as monodeprotonated
species at the SO2NH2 moieties) act as bidentate ligands, through the endocyclic N-3 and the NH- groups.
The proposed formulae of the new complxes are shown below. Except for the two Pb(II) complexes 13 and
20, as well as the AI(III) derivatives 14 and 16, which presumably are pseudo-octahedral, the other
derivatives are supposed to contain tetrahedral M(II) ions.
R
R
13"R = H2N
20" R= CICH2CONH
14: R = H2N
16: R = CICH2CONH
The compounds 6-20 together with the standard CA inhibitors 1-5 were assayed for inhibition
against three isozymes, hCA I, hCA II and bCA IV (Table III). As seen from the above data, the
chloracetamido derivative is more inhibitory than acetazolamide, methazolamide and dichlorophenamide,
whereas the unacylated compound 6 is less inhibitory than the above sulfonamides. The metal complexes 8-
20 are much more inhibitory than the sulfonamides from which they derive 6, 7 and than all other simple
sulfonamides assayed. They behave similarly to the metal complexes of acetazolamide, methazolamide or
dorzolamide previously reported by this group, which were all more inhibitory than the parent sulfonamide
from which were prepared [16-22, 40]. Particularly strong inhibition was observed for the Zn(II), Hg(II),
Pb(II) and Cd(II) complexes, especially against CA II and CA IV, the isozymes critical for aqueous humor
formation.
In vivo IOP lowering experiments were done in rabbits with some of the new compounds prepared
in the present work, such as the sulfonamides 6 and 7, and their Zn(II) complexes, which were among the
strong CA II and CA IV inhibitors in the obtained series. Some of the IOP lowering data at half an hour and
one hour after the instillation of one drop of 2 % solution of inhibitor within the rabbit eye are shown in
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Table IV, with dorzolamide (at the same concentration) as standard. In Fig. the time dependence of IOP
lowering with dorzolamide 5 and the two Zn(II) complexes 10 and 17 is presented.
Table III. CA inhibition data with the standard inhibitors 1-5, the sulfonamides 6 and 7, and their metal
complexes 8-20.
No Inhibitor KI (nM)
hCA Ia hCA IIa bCA IVb
1 Acetazolamide 900 12 220
2 Methazolamide 780 14 240
3 Ethoxzolamide 25 8 13
4 Dichlorophenamide 1200 38 380
5 Dorzolamide >50,000 9 43
6 1550 230 780
7 640 5 24
8 1050 190 540
9 350 110 220
10 50 15 25
11 40 14 19
12 12 7 10
13 80 10 26
14 240 76 110
15 120 5 12
16 80 4 16
17 40 3 9
18 40 3 10
19 9 2 5
20 15 5 10
a Human (cloned) isozymes; b From bovine lung microsomes.
Table IV: IOP lowering following topical application of CA inhibitors, half an hour and one hour after
instillation into the eye of a drop (50 L) of2 % solution of inhibitor.
Inhibitor lOP SE a
(mm Hg)
1/2 h lh
Dorzolamide 5 2.2 0.10 4.1 0.15
6 0 0.10 0 0.09
7 0 0.10 0 0.09
10 2.00.09 5.0 0.12
17 8.0 0.14 8.1 0.21
a IOP IOP control eye" IOP treated eye (N 3).
As seen from the above data, the sulfonamides 6 and 7 are totally ineffective as lOP lowering
agents, similarly to the classical clinically used inhibitors of type 1-5 [2,3]. On the other hand, dorzolamide,
the first topical sulfonamide used clinically in the treatment of glaucoma is an effective such agent, with a
decrease of lOP of around 4 mm Hg, one hour after administration directly into the eye (Table IV). From the
data of this table, it is obvious that the metal complexes of heterocyclic sulfonamides investigated by us
behave as much more effective IOP lowering agents than dorzolamide, and their effect is generally longer-
lasting (Fig. 1).
A last remark should be made about the possible mechanism of action of the new class of IOP
lowering agents. Obviously, their activity is due to inhibition of CA isozymes present in the cilliary
processes within the eye, similarly to other topically active sulfonamides [2-6]. The fact that the sulfonamide
per se is inactive via the topical route, whereas the metal complexes result much better than the drug
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dorzolamide, indicates that the presence ofmetal ions in the molecules of these CA inhibitors is essential and
confers them completely new properties.
.6-
-0
-10
Lowering ofIOP (ram Hg)
"||, /
",,, .7,
/
’",., ,< /
0 2
Time (hours)
Fig l" Time dependence of IOP lowering with dorzolamide (curve 1); the zinc complex 10 (curve 3) and the
zinc complex 17 (curve 3), after topical administration of one drop of 2 % solution of inhibitor in rabbit.
Preliminary results from this laboratory indicate that the metal complexes of topically active sulfonamides
show also increased lOP lowering effects with respect to the complexes prepared in the present study [42].
Our hypothesis is that the presence of the metal ion in the molecules of these complex inhibitors induces a
dramatic change in their physico-chemical properties as compared to those of the parent sulfonamide. This
phenomenon is certainly governed by the strong polarization induced by the metal ions. In this way, it is
quite probable that the right balance between the lipo- and hydrosolubility of these compounds is achieved,
which has been considered to be the critical factor for not observing topical activity in the classical CA
inhibitors, such as acetazolamide, methazolamide and ethoxzolamide, which were either too lipophilic or too
hy.drosoluble [2,3]. So, by choosing different metal ions and diverse sulfonamides, much larger possibilities
arise to finely tune the pharmacological properties which strongly influence the value of a drug.
In conclusion we describe here a novel class of lOP lowering agents, ie, the metal complexes of
sulfonamide CA inhibitors. These derivatives appear to be very active and longer lasting than the drug
dorzolamide, and might constitute the premises for a new generation of antiglaucoma drugs.
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